GlassScriptPhysician profile
Michael T Callaghan
NPI 1316978539
$1,585.62
in general payments reported to CMS, 2019-2025
33 companies · $569 in 2025
The $569 reported for 2025 was more than what 77% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $42.28 · 2021: $90.26 · 2022: $90.19 · 2023: $144 · 2024: $336 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $213.25 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $135.62 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.17 | 2019-2025 | Imfinzi |
| Merck Sharp & Dohme LLC | $82.78 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $79.81 | 2019-2023 | Jaypirca, Verzenio |
| Abbvie INC. | $75.37 | 2019-2025 | |
| Visionrt, INC. | $71.89 | 2019 | |
| Elekta, INC. | $62.45 | 2021-2024 | Elekta Medical Linear Accelerator |
| Amgen INC. | $56.86 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.50 | 2025 | Iclusig |
| Genentech USA, INC. | $48.44 | 2022-2024 | Phesgo, Tecentriq, Rituxan Hycela |
| Sumitomo Pharma America, INC. | $46.63 | 2024-2025 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $45.22 | 2021-2025 | Libtayo |
| Boston Scientific Corporation | $44.97 | 2022-2024 | Spaceoar Vue System - 10ml |
| Janssen Biotech, INC. | $43.70 | 2024-2025 | Talvey, Darzalex, Tecvayli |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.67 | 2019-2023 | |
| Sobi, INC | $41.25 | 2024-2025 | |
| Pfizer INC. | $34.66 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $31.23 | 2019 | |
| Incyte Corporation | $27.72 | 2020-2024 | Jakafi |
| Servier Pharmaceuticals LLC | $21.22 | 2025 | |
| Rigel Pharmaceuticals, INC. | $21.00 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Accuray Incorporated | $20.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.69 | 2023 | Ultomiris |
| Exelixis INC. | $18.66 | 2025 | Cabometyx |
| Siemens Medical Solutions USA, INC. | $18.64 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.27 | 2025 | Danziten |
| Seagen INC. | $16.12 | 2020 | |
| Heron Therapeutics, INC. | $15.87 | 2019 | |
| Agios Pharmaceuticals, INC. | $13.48 | 2019 | |
| Emd Serono, INC. | $13.24 | 2019 | |
| Medtronic USA, INC. | $12.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Callaghan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.